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The recent adaptation of CRISPRCas9 genome editing to Leishmania spp. has opened a new era in deciphering Leishmania biology.
The method was recently improved using a PCR-based CRISPR Cas9 approach, which eliminated the need for cloning. This new
approach, which allows high-throughput gene deletion, was successfully validated in L. mexicana and L. major. In this study, we
validated the toolkit in Leishmania donovani targeting the flagellar protein PF16, confirming that the tagged protein localizes to the
flagellum and that null mutants lose their motility. We then used the technique to characterise CK1.1, a member of the casein kinase
1 family, which is involved in the regulation of many cellular processes. We showed that CK1.1 is a low-abundance protein present
in promastigotes and in amastigotes. We demonstrated that CK1.1 is not essential for promastigote and axenic amastigote survival
or for axenic amastigote differentiation, although it may have a role during stationary phase. Altogether, our data validate the use of
PCR-based CRISPR Cas9 toolkit in L. donovani, which will be crucial for genetic modification of hamster-derived, disease-relevant
parasites.
1. Introduction
The protozoan parasite Leishmania is the causative agent of
leishmaniasis, which has several clinical forms depending
on the species, including cutaneous (e.g., L. major and
L. mexicana), diffuse cutaneous, mucocutaneous, and fatal
visceral leishmaniasis (e.g., L. donovani) [1, 2]. Leishma-
nia goes through several extracellular developmental stages
in the insect vector, from nonvirulent procyclic to viru-
lent metacyclic promastigote forms [3], and one intracel-
lular stage, the amastigote form, which resides inside the
phagolysosome of the mammalian host macrophages. In
recent years, omics systems-wide analyses, particularly RNA-
Seq, have been applied for many purposes such as the
determination of disease phenotype, the mode of action of
drugs, or the identification of drug-resistance markers [4,
5]. These technologies have also dramatically improved our
knowledge of Leishmania biology [4]. However, knowing
the genes that are differentially regulated under different
conditions is only the prelude to understand their role. This
is particularly important for Leishmania as more than 50%
of the genes encode hypothetical proteins [6]. One major
bottleneck for their characterisation is the absence of a Leish-
mania-specific genetic toolbox that could overcome different
parasite-specific limitations such as the absence of RNA-
interference machinery in the subgenus Leishmania, a stark
contrast to Trypanosoma brucei, where this technique greatly
contributed to a better understanding of the biology of this
parasite over the past decade [7, 8].
Although possible, genetic engineering has been partic-
ularly challenging and time-consuming in Leishmania para-
sites [9]. In locus tagging of a gene of interest (GOI) requires
multiple steps of cloning to assemble a cassette that could be
integrated at the 5󸀠 or the 3󸀠 end of the gene [10]. Furthermore,
the traditional gene targeting method involving homologous
recombination requires the generation of a cassette contain-
ing an antibiotic selection marker gene flanked by 300 to
900 bp of both the 5󸀠 and 3󸀠UTR of the GOI to direct integra-
tion into the genome [10, 11]. This strategy has many draw-
backs [12]: (i) for a diploid asexual organism such as Leish-
mania, at least two rounds of transfection are required [13],
and (ii) heterozygous transfectants need to be selected before
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the second round can be performed. The generation of
a knockout strain is thus time-consuming and can favor
misintegration of the targeting cassette elsewhere in the
genome or parasite compensatory adaptations if the deleted
gene is important for survival. This is particularly true for L.
donovani, as several studies have shown its ability to adapt
to stressful conditions by copy number variations leading to
gene amplification, gene deletion, or aneuploidy [14, 15]. This
genome instability further complicates genetic engineering,
as the presence of additional chromosomes requires addi-
tional rounds of transfection to obtain a complete deletion
of the GOI. A simpler and more efficient method is therefore
required to decipher L. donovani biology.
The clustered regularly interspaced short palindromic
repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) has
been used, since 2013, as a genome editing tool for a large
number of organisms including yeast and mammalian cells,
and has subsequently been adapted for several unicellular
human pathogens such as Plasmodium falciparum and Try-
panosoma cruzi [16]. The recent adaptation of CRISPR Cas9
for Leishmania spp. has opened a new era for Leishmania
genetic manipulation [17–19]. However these early methods
required the cloning of at least the single guide RNA (sgRNA)
in an expression vector, which increases the time necessary
to generate a knockout and prevent the use of these methods
to perform high-throughput gene tagging or deletions. In
a recent paper, Beneke et al. described the development of
a new PCR-based CRISPR Cas9 toolkit allowing rapid and
precise gene modification, which was successfully applied to
L.mexicana, L.major, andTrypanosoma brucei [20]. Parasites
stably expressing hSpCas9 and T7 RNA polymerase were
transfected with PCR fragments corresponding to the sgRNA
and the donor DNA cassettes to generate knockout or tagged
parasites in only one week. This method is perfectly suited to
generate knockout parasites in a high-throughput fashion, as
no cloning is required [20].The toolkit includes simple proto-
cols for gene deletions, or N- and C-terminal tagging as well
as a website to design overlapping oligonucleotides for the
PCRs (http://leishgedit.net/, [20]).
Casein Kinase 1 isoform 1 (CK1.1, LdBPK 351020.1) is
a member of the CK1 family, which are signalling ser-
ine/threonine protein kinases involved in the regulation of
various cellular processes such as the cell cycle or protein
trafficking [21]. They contain a highly conserved kinase
domain and a specific C-terminal domain that plays a key
role in their regulation and their localization [21, 22]. In
Leishmania, there are six isoforms, of which only two have
been studied: LdCK1.4 (LdBPK 2716800.1) and LdCK1.2
(LdBPK 351030.1). LdCK1.4 is secreted by the promastigotes
andmay play an important role in virulence and parasite sur-
vival [23]. LdCK1.2 (LdBPK 351030.1) is an ecto-/exokinase
released in the host cell via exosomes [24]. We showed that
this kinase is essential for parasite survival in mammalian
cells [25] and represents a validated drug target [26]. In con-
trast, LdCK1.1 has not yet been studied. Data available from
transcriptomic analyses suggest that CK1.1 is upregulated
in metacyclic promastigotes and in intracellular amastigotes
[27, 28], whereas proteomic data indicates that it is a very
low-abundance protein and, contrary to LdCK1.2, has not
been detected in exosomes [24, 29].
In this study, we first generated a Leishmania donovani
Bob cell line expressing Cas9 and T7 RNA polymerase. In
order to validate the CRISPR Cas9 toolkit in Leishmania
donovani, we targeted PF16 gene, which encodes a central
pair protein of the axoneme, essential for parasite motility.
We successfully deleted the PF16 gene, which resulted in loss
ofmotility, andwe obtained the expected flagellar localization
of PF16, by C-terminal tagging. We then applied the CRISPR
Cas9 toolkit for a first functional genetic analysis of CK1.1.
We showed that taggedCK1.1 proteinwas detected in both life
stages but at a very low level.We demonstrated that CK1.1 was
not essential for parasite survival as the null mutant parasites
could survive as promastigotes and axenic amastigotes but
may have a function in stationary phase.
2. Material and Methods
2.1. Leishmania donovani Culture and Axenic Amastigote Dif-
ferentiation. Axenic L. donovani strain 1S2D (MHOM/SD/
62/1S-CL2D) clone LdBob was obtained from Steve Bever-
ley, Washington University School of Medicine, St. Louis,
MO, and cultured as described previously [30–32]. Briefly,
105 logarithmic promastigotes per mL were incubated at
26∘C in M199 media (Gibco) supplemented with 10%
heat-inactivated FCS, 20mM HEPES, pH 6.9, 4.1mM
NaHCO
3
, 2mM glutamine, 8 𝜇M 6-biopterin, 10 𝜇g/mL folic
acid, 100 𝜇M adenine, 30 𝜇M hemin, 1x RPMI 1640 vita-
mins solutions (Sigma), 100U/mL of Penicillin/Streptomycin
(Pen/Step), and adjusted at pH 7.4. Axenic amastigotes were
obtained by incubating 106 logarithmic promastigotes permL
at 37∘C and 5%CO
2
in RPMI 1640 +GlutaMAX -I medium
(Gibco) supplemented with 20% of heat-inactivated FCS,
28mMMES, 2mM glutamine, 1x RPMI 1640 amino acidmix
(Sigma), 1x RPMI 1640 vitamins solutions (Sigma), 10𝜇g/mL
folic acid, 2mM glutamine, 100 𝜇M adenine, 100U/mL
of Pen/Step, and adjusted at pH 5.5. Relevant selective
drugs were added to the medium at the following con-
centrations: 30 𝜇g/mL hygromycin B (Invitrogen), 30𝜇g/mL
puromycin dihydrochloride (Sigma), and 20𝜇g/mL blasti-
cidin S hydrochloride (Invitrogen).When appropriate, axenic
amastigotes cell aggregates were dispersed by passing cell
suspensions five times through a 27-gauge needle before
analysis.
2.2. Analysis of the Percentage of Cell Death, Parasite Con-
centration, andmNeonGreen Fluorescence Intensity. Cultured
parasites were diluted in DPBS (Gibco) and incubated
with 2 𝜇g/mL propidium iodide (Sigma-Aldrich). Cells were
analysed with a CytoFLEX flow cytometer (Beckman Coul-
ter, Inc.) to determine the incorporation of propidium
iodide (ex𝜆 = 488 nm; em𝜆 = 617 nm) and to monitor
mNG levels in PF16::mNG::3xMyc (PF16-mNG-myc) or
CK1.1::mNG::3xMyc (CK1.1-mNG-myc) transgenic parasites
(ex𝜆 = 506 nm; em𝜆 = 517 nm). The percentage of cell death,
cell growth, and the mean mNeonGreen (mNG) fluores-
cence intensity were calculated using CytExpert (v2.0.0.153)
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software (Beckman Coulter, Inc.). Graphs were generated
with GraphPad Prism (v7.03).
2.3. Parasite Transfection. Parasite transfections were per-
formed as described previously [20]. 1 × 107 LdBob cells in
logarithmic phase were transfected with 15𝜇g of pTB007,
with or without PCR reactions (mock) in 1x Tb-BSF
buffer (90mM sodium phosphate, 5mM potassium chloride,
0.15mM calcium chloride, 50mMHEPES, pH 7.3) [33] using
2mm gap cuvettes (MBP) with program X-001 of the Amaxa
Nucleofector IIb (LonzaCologneAG,Germany). Transfected
cells were immediately transferred into 5mL prewarmed
medium in 25 cm2 flasks and left to recover overnight at 26∘C
before adding or not the appropriate selection drugs. Survival
of drug-resistant transfectants became apparent 7–10 days
after transfection.
2.4. PCR-Amplification of the Targeting Fragments and
the sgRNA Templates. PCR reactions were performed as
described previously [20]. Briefly, for the PCR-amplification
of the targeting fragments of pPLOT and pT cassettes, 30 ng
circular pPLOT or pT plasmid, 0.2mM dNTPs, 2 𝜇M each
of gene-specific forward and reverse primers, and 1 unit HiFi
polymerase (Roche) were mixed in 1x HiFi reaction buffer
(Roche), supplemented with 1.875mMMgCl
2
to reach a final
concentration of 3.375mM and 3% (v/v) DMSO. The PCR
conditions were as follows: 5min at 94∘C then 40 cycles of
30 s at 94∘C, 30 s at 65∘C, and 2min 15 s at 72∘C, and lastly
a final elongation step of 7min at 72∘C. The presence of the
expected product was assessed by running 2 𝜇L of the 40 𝜇L
reaction on a 1% agarose gel. The sample was then heat-
sterilized at 94∘C for 5min and used for transfection without
further purification. Primer sequences are detailed in Table
S1 in Supplementary Materials.
In order to amplify the sgRNA templates, 0.2mMdNTPs,
2 𝜇M each of primer G00 (sgRNA scaffold), 2𝜇M of gene-
specific forward primer, and 1 unit HiFi polymerase (Roche)
were mixed in 1x HiFi reaction buffer with MgCl
2
(Roche).
The PCR conditions were 30 s at 98∘C followed by 35 cycles
of 10 s at 98∘C, 30 s at 60∘C, and 15 s at 72∘C and a final
elongation step of 7min at 72∘C. To assess the presence of
the expected product, 2 𝜇L of the 20𝜇L reaction was run on
a 1% agarose gel. The sample was heat-sterilized at 94∘C for
5min and transfected without further purification. Primer
sequences are detailed in Supplementary Materials in Table
S1.
2.5. Diagnostic PCR. To assess the loss of the target gene
in the knockout cell lines, genomic DNA was isolated from
parasites collected after 1 passage post-transfection with
the DNeasy Blood & Tissue Kit (Qiagen). One hundred
nanograms of genomicDNAwasmixed with 0.3mMdNTPs,
0.5 𝜇M forward primer and reverse primer, 3% (v/v) DMSO,
2.5 units LongAmp Taq DNA polymerase (NEB), and 1x
LongAmp Taq Reaction Buffer supplemented with Mg2+
(2mM final, NEB). The PCR conditions were 5min at 94∘C
followed by 35 cycles of 30 s at 94∘C, 30 s at 60∘C, 2min
30 s at 65∘C, and a final elongation step of 10min at 72∘C.
Three microliters of reaction was then run on a 1% agarose
gel to assess for the presence of the expected product. Primer
sequences are detailed in Supplementary Materials in Table
S2.
2.6. Protein Extraction, SDS-PAGE, andWestern Blot Analysis.
Between 5 × 107 and 2 × 108 logarithmic phase parasites
(depending on the experiment) were resuspended in RIPA
lysis buffer containing 150mMNaCl, 1%TritonX-100, 20mM
TrisHCl, pH7.4, 1%Nonidet P-40, 1mMEDTA, and inhibitor
cocktails for proteases (Roche Applied Science, IN) and
supplemented with 1mM sodium orthovanadate and 1mM
PMSF.The cells were sonicated using theBioruptor (Diagen-
ode) with the high power mode for 5min (sonication cycle:
10 sec ON, 20 sec OFF) followed by 5 more minutes (soni-
cation cycle: 30 sec ON, 30 sec OFF) and then centrifuged.
Total protein quantity was assessed by the Pierce Coomassie
Plus (Bradford) Assay. Twenty micrograms of total proteins
was denatured, separated by SDS-PAGE, and transferred
onto polyvinylidene difluoride (PVDF) membranes (Pierce).
Depending on the experiment, proteins were revealed as
described in Supplementary Materials in Table S3, using
the following primary antibodies at the indicated dilutions:
(i) anti-CK1.2 antibody (1/500, [25]), (ii) anti-myc antibody
(1/1000, Biosensis R-1319-100), anti-FlagM2 antibody (1/1000,
Sigma F3165); and secondary antibodies: anti-rabbit antibody
(1/20000, Thermo Scientific 31462) and anti-mouse antibody
(1/20000, Thermo Scientific 32230). Proteins were revealed
by SuperSignal West Pico Chemiluminescent Substrate
(Thermo Scientific) using the PXi image analysis system
(Syngene) at various exposure times.
2.7. Fluorescence Microscopy. L. donovani promastigotes
expressing the fluorescent fusion protein PF16-mNG-myc
were imaged by live microscopy. Samples were prepared as
previously described [34]. Briefly, parasites were harvested
from logarithmic phase culture by centrifugation at 800𝑔 for
5min and washed three times in PBS with Hoechst 33342
at 5 𝜇g/mL. The cells were resuspended in 50 𝜇L PBS, and
2 𝜇L was placed on a microscope slide, then a coverslip was
applied, and the cells were immediately imagedwith a 60xNA
1.42 plan-apochromat oil immersion objective lens (Olympus
AMEP4694) on a EVOS FL microscope (Thermo Fischer
Scientific, AMF4300) with a ICX445 monochrome charge-
coupled device (CCD) camera (Sony) at room temperature.
2.8. Parasite Tracking. Leishmania promastigotes from early
stationary phase were filmed for 10 s (200 frames) with a
Leica DMI 4000B microscope, using a 40x objective and an
Evolv EMCCD camera, with Metaview software. Tracking
was performed using the Spot Detector and Spot Tracking
tools from Icy software [2], with defaults settings and the
followingmodifications: Spot Detector: Scale 3, Sensitivity 80
(∼7 pix); size filtering: min = 10 – max = 300.
2.9. Bioinformatics. Multiple sequence alignments (MSA)
were computed using the PSI-Coffee mode of T-Coffee [35].
The resulting alignments were visualized using Clustalw
(1.83).
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Figure 1: Constitutive expression of Cas9 in L. donovani Bob strain. (a) Proteins were extracted from LdBob (LdB) or LdBob expressing
Cas9-FLAG (LdB pTB007, 162 kDa) promastigote in logarithmic phase. Twenty micrograms was analysed by Western blotting using the
anti-FLAG M2 antibody (right panel). The Coomassie-stained membrane of the blot is included as a loading control (left panel). Protein
weight in kDa is indicated on the left. (b) Logarithmic phase promastigotes were seeded at 1 × 105 promastigotes/mL and cultured for 8
days. Samples were collected every 24 h to assess cell number (black symbol) and percentage of cell death (white symbol) by flow cytometry
in triplicate in two independent experiments. Cell lines: LdB (square) and LdB pTB007 (circle). (c) Proteins were extracted from LdBob or
LdBob expressing Cas9-FLAG (LdB pTB007, 162 kDa) axenic amastigotes (48 h after temperature and pH shift) and processed as described
in (a). (d) Logarithmic phase promastigotes were seeded at 1 × 106 promastigotes/mL, shifted to 37∘C and pH 5.5 and cultured for 5 days.
Samples were collected and treated as described in (c).
3. Results and Discussion
3.1. Expression of Cas9 and T7 RNA Polymerase Does Not
Affect Parasite Growth and Differentiation. We first trans-
fected LdBob promastigotes with the plasmid pTB007 (LdB
pTB007) expressing (i) the humanized Streptococcus pyo-
genes Cas9 nuclease gene (hSpCas9) [36] with a nuclear
localization signal and three copies of the FLAG epitope at
the N-terminus, (ii) T7 RNA polymerase (T7 RNAP) and
(iii), a hygromycin resistance gene [20]. We confirmed the
expression of Cas9 byWestern blot analysis (Figure 1(a)) and
showed that this expression did not alter the growth of L.
donovani promastigotes (Figure 1(b)), similar to what has
been shown with L. mexicana promastigotes [20]. We found
that Cas9 is also expressed in axenic amastigotes (Figure 1(c)).
The presence of pTB007 did not interfere with axenic
amastigote differentiation or proliferation (Figure 1(d)) but
surprisingly has a slight positive effect on cell survival in late
stationary phase.
3.2. Validation of the CRISPR Cas9 Gene Editing Toolkit in
L. donovani. To assess the efficiency of the CRISPR Cas9
gene editing toolkit in L. donovani, we performed C-terminal
tagging and the generation of null mutants on the well-
studiedPF16 gene (LdBPK 201450.1), which encodes a central
pair protein of the flagellar axoneme. Previous experiments
in L. mexicana showed flagellar localization of PF16, and
its deletion abrogates parasite motility [20]. We sought to
replicate these phenotypes in L. donovani using the same gene
editing strategy to validate the toolkit in this parasite species.
To fuse PF16 with the mNeonGreen-3xmyc (mNG-myc)
in LdBob, we produced two PCR fragments: the donor
DNA cassette, containing mNG-myc and the puromycin-
resistance marker, as well as the sgRNA template to gen-
erate a Cas9 cleavage downstream of the PF16 gene [20].
It is crucial to know the exact sgRNA sequence and
protospacer-adjacent motif (PAM) to successfully tag or
delete genes in Leishmania spp. usingCRISPRCas9.There are
important differences between the genome of LdBPK282A1
BioMed Research International 5
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Figure 2: L. donovani PF16 null mutants are immotile. LdB pTB007 or LdB pTB007 ΔPF16 promastigotes in logarithmic phase were filmed
for 10 s (200 frames). The tracking of individual parasites was performed using the Spot Detector and Spot Tracking tools from Icy software.
Images were taken with a Leica DMI 4000B microscope, using a 40x objective and an Evolv EMCCD camera, with Metaview software.
reference strains from South-Eastern Nepal [37] and that
of LdBob, a strain derived from the Sudanese isolate
Ld1S2D (MHOM/SD/62/1S-CL2D [38]). Thus, we used
an unpublished Ld1S2D reference genome (PRJNA396645,
https://www.ncbi.nlm.nih.gov/bioproject/396645) to design
the primers required to generate the donor DNA and the
corresponding sgRNAs. Sequences were identified using the
EuPaGDT CRISPR gRNA Design Tool [39] with similar tar-
get parameters as those used in the LeishGEdit strategy [20].
LdB pTB007 promastigotes were then transfected with the
two PCR fragments. The transgenic parasites were selected
using puromycin; the correct integration of the tagging
cassette was confirmed by the detection of the tagged protein
using microscopy and Western blot analysis with an anti-
myc antibody (Figures S1A and B). The localization of the
tagged protein was consistent with the known localization of
PF16 [20]. Fluorescence intensity measurements showed that
its abundance is constant during promastigote growth and
that the expression of the mNG-myc reporter fused to the C-
terminus of PF16 does not lead to any growth defects (Figure
S1C). These data indicate that the tagging of PF16 using
CRISPR Cas9 was successful in L. donovani. This approach
is simple and fast and will greatly improve the way we study
Leishmania genes compared to previous methods of gene
tagging (e.g., by expressing GOI fused to a fluorescent tag
from an episome), since part of their endogenous regulation
may be better maintained through the conservation of either
the 5󸀠 or 3󸀠UTR (depending whether the tagging is at the C-
or N-terminus, resp.).
Next, we targeted the PF16 locus to generate null mutants
in a single round of transfection. LdB pTB007 promastigotes
were transfected with four PCR fragments corresponding to
the two sgRNA templates to generate a double-strand break
upstream and downstream of the PF16 CDS, and the two
repair cassettes containing the resistance marker genes for
blasticidin and puromycin [20].We confirmed the generation
of a double drug-resistant cell population by PCR (Figure
S2A), indicating that PF16 has been successfully deleted in
the whole population, without the need for subcloning as
observed previously with L. mexicana and L. major [20]. The
ΔPF16 mutant grew similarly to the parental strain (data not
shown), only displaying a loss of motility (Figure 2), which is
consistent with published data [20, 40, 41]. Altogether, these
data validate the use of the CRISPRCas9 toolkit developed by
Beneke et al. in L. donovani [20].This approachwill overcome
the two main limitations for the genetic manipulation of L.
donovani. First, because L. donovani adapts very fast to its
environment by copy number variations [15], the ability to
generate homozygote knockouts in one single transfection
will minimise the introduction of compensatory mutations,
which could mask the phenotype of the knockouts. This
is therefore a major improvement compared to previous
methods for gene deletion [42]. Second, L. donovani strain
Ld1S2D, purified from the spleen or the liver of infected
hamsters, is particularly sensitive to in vitro culture, as
this strain loses virulence after only 5 to 10 passages in
culture to become unable to infect hamsters ([38] and our
unpublished data). Thus, minimising time in culture is a
prerequisite for virulence studies; hence this CRISPR Cas9
method will enhance our ability to conduct such studies in L.
donovani, one of the causative agents of the only lethal form
of leishmaniasis.
3.3. Leishmania CK1.1 Member of the Casein Kinase Family Is
More Closely Related to CK1.2 Than to Other CK1s. LdCK1.1
(LdBPK 351020.1) is 324 amino acids long and has a predicted
molecular weight of 37.2 kDa. It contains a kinase domain,
a N-terminal domain longer than that of CK1 of other
eukaryotes including LdCK1.2, but similar to that of TbCK1.1,
and a C-terminal domain shorter than that of the human
CK1 (𝛼, 𝛿, and 𝜀), LdCK1.2, or TbCK1.2, but similar to
that of TbCK1.1 (Figure 3(a)). LdCK1.1 is closely related to
LdCK1.2, with 67% identity in protein sequence [25]. As the
two encoding genes are adjacent on chromosome 35, they
probably originated from the same gene that duplicated and
then evolved differently [25]. The most striking difference
6 BioMed Research International
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Figure 3: Amino acid sequence alignment of Leishmania Casein Kinase I proteins. (a) The amino acid sequences of LdCK1.1 (Leishmania
donovani LdBPK 351020.1, E9BRX8), TbCK1.1 (Trypanosoma brucei Tb927.5.790, Q57W24), TcCK1.1 (Trypanosoma cruzi TcCLB.508541.220,
Q4DN97), TgCK1 (Toxoplasma gondii CK1, Q6QNM1), PfCK1 (Plasmodium falciparum CK1, C6S3F7), SpCK1 (Schizosaccharomyces pombe
hhp1, P40235), hsCK1𝛼 (human CSNK1A1, P48729), HsCK1𝛿 (human CSNK1D, P48730), and HsCK1𝜀 (human CSNK1E, P49674) have been
compared and the alignments were computed using theM-Coffeemode of T-Coffee.The resulting alignments were visualized using Clustalw.
∗ corresponds to amino acid residues that are invariant in all four CK1s. The dotted line marks the N-terminal domain, the black line marks
the C-terminal domain, and the rest is the kinase domain. (b) The amino acid sequences of LdCK1.1 and LdCK1.2 (LdBPK 351030.1) have
been compared and the alignments were computed using the M-Coffee mode of T-Coffee. The resulting alignments were visualized using
Clustalw. ∗ corresponds to amino acid residues that are invariant in all four CK1s.
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Figure 4: Successful in locus tagging of L. donovani CK1.1 with mNG-myc tag. (a) Proteins were extracted from LdB pTB007 or LdB CK1.1-
mNG-myc promastigotes in logarithmic phase and twenty micrograms was analysed by Western blotting using an anti-Myc tag antibody
(Top panel).The Coomassie-stained membrane of the blot is included as a loading control (bottom panel). Protein weight in kDa is indicated
on the left. The expected size of the fusion protein is 69,8 kDa. The lower band indicated with an asterisk (∗) may be a result of protein
degradation. (b) Promastigotes were seeded at 1 × 105 promastigotes/mL and cultured for 7 days, and aliquots were taken every 24 h for
analysis. Cell number (black symbol) and mNeonGreen fluorescence intensity (white symbol) were assessed by flow cytometry in triplicate
in two independent experiments. Fluorescence intensity of the LdB pTB007 strain was used for normalization. Cell lines: LdB pTB007 (circle)
and LdB pTB007 CK1.1-mNG-myc (diamond). (c) Similar to (b), except that promastigotes were seeded at 1 × 106 promastigotes/mL, shifted
to 37∘C and pH5.5 and cultured for 6 days. (d) Similar to (a), except that proteins were extracted from LdB pTB007 or LdB CK1.1-mNG-myc
axenic amastigotes (48 h after temperature and pH shift).
is the lack of 33 amino acids in the C-terminal domain of
LdCK1.1 compared to that of LdCK1.2 (Figure 3(b)). Since the
C-terminal domain is particularly important for the localiza-
tion and the regulation of CK1 family members, these data
suggest that CK1.1 and CK1.2 could have different localization
and function [22]. LdCK1.1 has an orthologue in T. brucei
TbCK1.1 (Tb927.5.790, 60% identity) and in T. cruzi TcCK1.1
(TcCLB.508541.220, 63% identity), which are also adjacent to
TbCK1.2 and TcCK1.2, respectively.The two isoforms present
inT. cruzi have a distinct feature compared to the orthologues
in other trypanosomatids; TcCK1.2 is encoded by an array of
five copies, while TcCK1.1 is encoded by a single copy (CL
Brener-Esmeraldo-like strain [43]). Finally, LdCK1.1 shows
57% identity with the human CK1 𝛿, compared to 67% for
LdCK1.2. Previously we showed that Leishmania CK1.2 is the
most conserved kinase in Leishmania, and the kinase with the
most similarity to its human orthologues [25], leading to the
hypothesis that CK1.2 could have a function outside of the
parasite by mimicking the host CK1.These characteristics are
not shared by CK1.1, suggesting that it could be essentially
intracellular; this hypothesis is supported by proteomics data
showing that CK1.1 is not detected in Leishmania exosomes
[24].
3.4. Leishmania donovani CK1.1 Is a Nonessential Kinase
WhichMay Play a Role in Stationary Phase. Next, we applied
the CRISPR Cas9 toolkit to gain insight into CK1.1 function
in the parasite. We tagged the protein to determine its
localization and we deleted it to determine whether this
kinase is essential for promastigote or amastigote survival.
To generate transgenic parasites expressing CK1.1-mNG-
myc from the endogenous locus, we cotransfected LdB
pTB007 promastigotes with a sgRNA cassette targeting the 3󸀠
end of CK1.1 and a repair cassette containing the puromycin-
resistance marker and the mNG-myc tag in frame. We then
performed a Western blot analysis to determine whether
CK1.1-mNG-mycwas expressed in the transfected promastig-
otes and revealed a band at about 70 kDa corresponding to the
expected size of the tagged protein (Figure 4(a)). Using FACS
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analysis to measure cell density, we showed that the parasites
expressing CK1.1-mNG-myc displayed no change in growth
phenotype at the promastigote stage (Figure 4(b)). CK1.1
shows comparable expression in logarithmic and stationary
phase (Figure 4(b)), although at a lower level than PF16-
mNG-myc, as judged by Western blot and FACS analysis
(Figures S1B and S1C). Promastigotes expressing CK1.1-
mNG-myc could differentiate into axenic amastigotes that
proliferated at a rate similar to the control cells (Figure 4(c)).
CK1.1-mNG-myc is also detected in amastigotes, as shown
Figure 4(d), with slightly higher levels in logarithmic phase
than in stationary phase (Figure 4(c)). Altogether, these data
suggest that CK1.1 is a low-abundance protein, explaining
why we could barely detect the protein above background,
using a fluorescence microscope (data not shown). This
finding is consistent with proteomic data showing that CK1.1
in L. donovani or in L. major [30] could only be detected
with 1 peptide [29] and in T. brucei where TbCK1.1 was not
detected contrary to TbCK1.2 [44, 45].
To determine whether CK1.1 is essential for parasite
survival, we generated a CK1.1 null mutant in L. donovani.
We performed a cotransfection of LdB pTB007 promastigotes
with two sgRNA cassettes targeting the 5󸀠 and the 3󸀠 end of
CK1.1 and two repair cassettes containing, respectively, the
puromycin and the blasticidin-resistance genes. We obtained
parasites that were resistant to both drugs and confirmed
the correct integration of the puromycin and blasticidin-
resistance genes at CK1.1 locus and the complete loss of
CK1.1 by PCR as shown in Figure 5(a). Similarly to PF16,
CK1.1 was deleted in the whole population in one single
transfection, confirming once again the remarkable efficiency
of this method. The generation of homozygous ΔCK1.1 para-
sites indicates that LdCK1.1 is not essential for promastigote
survival. We did not observe any growth defect except in sta-
tionary phase, where the cell density of the ΔCK1.1 was lower
than that of the control parasites (Figure 5(b)). Although the
percentage of cell death, as measured by propidium iodide
(PI) incorporation, was slightly higher in ΔCK1.1 parasites
(4%) than in control parasites (2%), it remained below 5%
which thus could not entirely explain the decrease in cell
density. However, when cells contain fragmented DNA or
when they lose their DNA (zoids), the percentage of PI+ cells
no longer corresponds to the real percentage of dead cells.We
investigated this hypothesis by measuring the ΔCK1.1 DNA
content in stationary phase using FACS analysis, and found
no differences in the DNA content of ΔCK1.1 compared to
that of control parasites (data not shown).We did not observe
an increase in fragmented DNA or cell debris (data not
shown), suggesting that the difference in cell density might
not be a consequence of cell death. Interestingly, these data
indicate that CK1.2 cannot compensate for the loss of CK1.1
and conversely, the absence of CK1.1 does not influence the
regulation of CK1.2 abundance. Indeed, there is no difference
in CK1.2 level between the mutant and the control strains
in promastigotes (Figure 5(c), left panel) or in amastigotes
(Figure 5(c), right panel). These results suggest the absence
of a regulatory feedback loop between the two kinases,
supporting the hypothesis that they might have different
functions. We did not observe any morphological differences
between ΔCK1.1 and control parasites (data not shown).
We investigated whether promastigotes could undergo
axenic amastigote differentiation in the absence of CK1.1.
We showed that they could differentiate and similar to what
we observed in promastigotes, they could proliferate as well
as control parasites (Figure 5(d)); however, ΔCK1.1 parasites
present a higher percentage of cell death in stationary phase
(about 40%) than the control parasites (about 20%). This
cell mortality, exclusively restricted to the amastigote stage,
as we did not observe this phenomenon in promastigotes
(Figure 5(b)), indicates that CK1.1 could have a role in late
stationary phase. These data demonstrate that CK1.1 is not
essential for amastigote survival, which is consistent with
observations inT. brucei showing that TbCK1.1 is not essential
for bloodstream form survival contrary to TbCK1.2 [46].
Overall, our data demonstrate that CK1.1 is not essential
for parasite survival and axenic amastigote differentiation
but could have a role in the regulation of processes linked
to stationary growth phase. Conversely, we have previously
shown that CK1.2 is essential for the survival of axenic and
intracellular amastigotes [25], suggesting these two related
kinases have evolved independently. Evolution of the two
isoforms is similar in T. brucei where TbCK1.2 is essential
for cell survival, but not TbCK1.1 [46]. Altogether, these data
suggest that CK1.1 andCK1.2 have evolved similarly in the two
major trypanosomatids.
4. Conclusion
In this study, we validated the CRISPR Cas9 toolkit for Leish-
mania donovani targeting PF16. Gene editing and particularly
PCR-based CRISPR Cas9 methods will have a major impact
on our ability to study the biology of L. donovani.The fact that
only one single transfection is required to obtain knockout
mutants will (i) dramatically limit parasite adaptation, by
decreasing any compensatory mutation that could mask the
phenotype, and (ii) allow the use of hamster-derived parasites
for genetic manipulation by preventing the nonspecific loss
of virulence occurring during in vitro culture. The use of
CRISPR Cas9 in hamster-derived L. donovani opens new
possibilities of studying the phenotype of nonessential genes
in the context of the relevant mammalian host, thus moving
beyond in vitro studies for the medically most relevant
Leishmania spp.
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Figure 5: CK1.1 is nonessential in L. donovani. (a) PCR analysis of the ΔCK1.1 cell line. Diagrams showing the CK1.1 locus and PCR primers
(small arrows) used to test for the presence of the CK1.1 CDS or the correct integration of puromycin and blasticidin drug-resistance genes
(top panel). PCR products run on an agarose gel to assess the correct integration of the puromycin-resistance gene (P), blasticidin-resistance
gene (B), and the presence/absence of the CK1.1 CDS (bottom panel). Fragments sizes in kb are indicated on the left. (b) Promastigotes were
seeded at 1 × 105 promastigotes/mL and were cultured for 8 days. Aliquots were taken every 24 h to assess cell number (black symbol) and
percentage of death (white symbol) by flow cytometry in triplicate from two independent experiments. Cell lines: LdB pTB007 (circle), LdB
pTB007 ΔCK1.1 (diamond). (c) Proteins were extracted from LdB pTB007 or LdB pTB007 ΔCK1.1 promastigotes in logarithmic phase (right
panel) and axenic amastigotes 48 h after temperature and pH shift (left panel) and twentymicrograms was analysed byWestern blotting using
an anti-CK1.2 antibody (Top panel). The Coomassie-stained membrane of the blot is included as a loading control (bottom panel). Protein
weight is in kDa is indicated on the left. (d) Similar to (b), except that promastigotes were seeded at 1×106 promastigotes/mL, shifted to 37∘C
and pH 5.5 and cultured for 6 days.
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